Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Filtros adicionais











Intervalo de ano
1.
J Diabetes Investig ; 2019 May 18.
Artigo em Inglês | MEDLINE | ID: mdl-31102326

RESUMO

AIMS/INTRODUCTION: To investigate the efficacy/safety of dulaglutide once-weekly monotherapy versus glimepiride in Chinese patients with type 2 diabetes. MATERIALS AND METHODS: This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study. Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks. The primary objective of the study was to investigate the non-inferiority of dulaglutide 1.5 mg versus glimepiride by the change from baseline to week 26 in glycated hemoglobin (non-inferiority margin 0.4%). RESULTS: Dulaglutide 1.5 mg and 0.75 mg were non-inferior (P < 0.001) and superior (P ≤ 0.002) versus glimepiride for the change in glycated hemoglobin from baseline to week 26. The least-squares mean differences (95% confidence interval) versus glimepiride were dulaglutide 1.5 mg, -0.53% (-0.74, -0.32) and dulaglutide 0.75 mg, -0.32% (-0.53, -0.12). Significantly more patients attained glycated hemoglobin <7.0% at week 26 in the dulaglutide 1.5 mg (71.7%) versus the glimepiride (57.5%; P = 0.005) group. The decrease from baseline to week 26 in fasting blood glucose was significantly more pronounced in both the dulaglutide groups versus the glimepiride group (P < 0.01). The overall incidence and rate of hypoglycemia were lower in both of the dulaglutide groups versus the glimepiride group. At week 26, bodyweight had increased from baseline in the glimepiride group and decreased from baseline in both dulaglutide groups. The most frequent gastrointestinal drug-related adverse events with dulaglutide were diarrhea, abdominal distension, nausea and vomiting. CONCLUSIONS: These findings support once-weekly dulaglutide monotherapy as a treatment for Chinese patients with early stage type 2 diabetes.

2.
J Diabetes Complications ; 30(8): 1609-1613, 2016 Nov - Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27496253

RESUMO

AIMS: This study was to determine whether serum glycated albumin (GA) was a better indicator of glycemic control than hemoglobin A1c (HbA1c) when starting a new treatment regimen for type 2 diabetes. METHODS: Newly diagnosed type 2 diabetes patients, or patients who had poor glycemic control with oral hypoglycemic agents, were enrolled at 10 hospitals in Beijing. Serum GA, HbA1c, fasting blood glucose (FBG), and C-peptide were assayed on Days 0, 14, 28, and 91 after treatment. RESULTS: Four hundred ninety-nine patients were enrolled. Mean FBG, GA and HbA1c decreased significantly in patients at Days 14, 28, and 91. In patients with improved glycemic control, the reduction of GA and HbA1c levels was 10.5±13.3% vs. 5.1±5.4% on Day 14, 16.0±13.4% vs. 9.0±7.0% on Day 28, and 18.0±16.7% vs. 18.3±9.4% on Day 91, respectively, compared with baseline values. Changes in GA on Day 14, 28 and 91 were all closely correlated with changes in HbA1c on Day 91. Change in GA on Day 14 was correlated with treatment effectiveness evaluated by HbA1c on Day 91. CONCLUSIONS: GA may be a useful marker for assessing glycemic control at an early stage of new diabetes treatment and assist in guiding adjustments to treatment and therapy.


Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Hemoglobina A Glicada/análise , Albumina Sérica/análise , Glicemia/análise , Diabetes Mellitus Tipo 2/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos
3.
J Geriatr Cardiol ; 9(3): 228-36, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23097651

RESUMO

OBJECTIVES: To evaluate the plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus (T2DM) and arteriosclerosis obliteran (ASO) when treated with Probucol plus Cilostazol in combination and individually. METHODS: In this open-label study, patients aged 40-75 years were randomized to receive conventional therapy alone, or with Cilostazol 100 mg bid, or with Probucol 250 mg bid, or with both in combination. Endpoints included changes in plasma biomarker and safety at 12 weeks. RESULTS: Of the 200 randomized patients, 165 for per-protocol and 160 for the safety (QTc intervals) were set, respectively. Probucol significantly reduced total cholesterol (P < 0.001), low-density lipoprotein cholesterol (LDL-C), (P = 0.01), and high-density lipoprotein cholesterol (HDL-C) (P < 0.001) compared with conventional therapy. Cilostazol was effective in increasing HDL-C (P = 0.002) and reducing triglycerides levels (P < 0.01) compared with conventional therapy. A trend towards significance was observed for the difference between conventional therapy alone and Probucol plus Cilostazol group for the change in oxidized low-density lipoprotein (Ox-LDL, P = 0.065). No significant effects on the majority of the remaining biomarkers were found across the treatment groups. CONCLUSIONS: We have confirmed that Ox-LDL could be a possible plasma atherosclerotic biomarker among the evaluated biomarkers, which reflected the synergetic effect of Cilostazol plus Probucol in patients with T2DM and ASO shown previously in preclinical studies.

4.
Artigo em Inglês | MEDLINE | ID: mdl-17110157

RESUMO

A new method has been established for the determination of aminomethylbenzoic acid using sodium 1,2-naphthoquinone-4-sulfonate as the chemical derivative chromogenic reagent. This method is based on the formation of a pink compound from the reaction of aminomethylbenzoic acid and sodium 1,2-naphthoquinone-4-sulfonate. The nucleophilic substitution reaction proceeds quantitatively in pH 12.0 buffer solution. The stoichiometric ratio of the reaction, maximum absorption wavelength and the value of epsilon(430) were 1:1, 430 nm, and 2.87 x 10(3)L mol(-1)cm(-1), respectively. Beer's law was obeyed in the range of 0.80-80 mg/L of aminomethylbenzoic acid. The data have been filled to a linear regression equation A=0.03183+0.01658C (mg/L), with a correlation coefficient of 0.9996. The detection limit is 0.11 mg/L, R.S.D. is 0.54%, and average recovery is over 99.6%. This paper further improves the determination of aminomethylbenzoic acid compared to the previous methods. The kinetic property and reaction mechanism have also been discussed. This proposed method has been successfully applied to the determination of aminomethylbenzoic acid in injection of aminomethylbenzoic acid with satisfactory results.


Assuntos
Compostos Cromogênicos/química , Naftoquinonas/química , para-Aminobenzoatos , Ácido 4-Aminobenzoico/urina , Calibragem , Humanos , Concentração de Íons de Hidrogênio , Cinética , Reprodutibilidade dos Testes , Soluções/química , Solventes/química , Tensoativos/química , Temperatura Ambiente , Fatores de Tempo
5.
Guang Pu Xue Yu Guang Pu Fen Xi ; 24(8): 995-8, 2004 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-15766129

RESUMO

In the presence of mixed surfactant cetyl trimethyl ammonium bromide(CTMAB) and Tween80, the photometric analysis properties of color reaction of 3,5-dibronosalicyl fluorone (DBSAF) with tungsten(VI) were studied. The experimental result showed that tungsten(VI) reacted with DBSAF to form a micelle complex with a maximum absorption at 527 nm in a 0.60 mol x L(-1) hydrochloric acid medium. The mixed surfactant remarkably improved the sensitivity of the method and the dissolubility of the complex. The apparent molar absorptivity of the complex is 2.64 x 10(5) L x mol(-1) x cm(-1) at 527 nm. Tungsten (VI) reacted with DBSAF to form a complex with a stoichiometric ratio of 1:2, which was determined by mole ratio method and continual method of transformation, respectively. Beer's law was obeyed in the range of 0-400 microg tungsten (VI) per L. The proposed method has been applied to the determination of trace amount of tungsten in alloy steel samples.

6.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao ; 25(6): 680-4, 2003 Dec.
Artigo em Chinês | MEDLINE | ID: mdl-14714311

RESUMO

OBJECTIVE: To study the cell biological mechanism of sodium selenite improving insulin sensitivity in pubertal rats with insulin resistance. METHODS: The content of inositol 1,4,5-trisphosphate (IP3) was examined by anion resin chromatography, and mRNA levels of phosphatidylinositol 3-kinase regulatory subunits (PI3Kp85 alpha) and Se-P were detected by RT-PCR in hepatocyte isolated from pubertal rats with insulin resistance. RESULTS: The mRNA levels of Se-P and PI3Kp85 alpha and content of IP3 in isolated hepatocyte decreased in pubertal male rats with insulin resistance. The above indices increased and reached normal level in rats supplied with selenium. The response to insulin stimulation in isolated hepatocyte in rats with selenium supply was similar to that in the control group, and both groups had higher response than those with high-fat diet. Alone when inhibited by wortmannin, the concentration of IP3 increased slightly in rats with selenium supply, but still was lower than that in the control group. CONCLUSIONS: These results indicate that the effect of selenium improving insulin sensitivity may be related to phosphatidylinositol PI3K signalling pathway. The effect of regulation of IP3 by selenium is not as effective as that by insulin, which may explain the difference of effect between selenium and insulin.


Assuntos
Hepatócitos/citologia , Resistência à Insulina , Insulina/farmacologia , Selenito de Sódio/farmacologia , Animais , Separação Celular , Hepatócitos/metabolismo , Inositol 1,4,5-Trifosfato/análise , Masculino , Fosfatidilinositol 3-Quinases/análise , Proteínas/análise , RNA Mensageiro/análise , Ratos , Ratos Wistar , Selenoproteínas , Transdução de Sinais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA